ProPhase Labs, now trading on the OTC Markets, filed its quarterly report for the period ending March 31, 2026, and the numbers paint a stark picture of a company under severe financial strain. The company has moved from a modest equity cushion to a deficit, meaning its liabilities now exceed its assets.
The Financial Deterioration
The headline figure is the swing in stockholders' equity. At the end of 2025, the company reported positive equity of $3.5 million. Three months later, that figure has collapsed to a deficit of $614,000. This was driven by a net loss of $5.4 million for the quarter, a significant acceleration from the $4.7 million operating loss reported in the same period a year earlier.
The balance sheet reveals the pressure is acute. Cash and cash equivalents fell to just $31,000, down from $90,000 at the start of the year. Meanwhile, current liabilities have grown to $56.1 million, dominated by $14.2 million in standard accounts payable and another $27.6 million owed to unconsolidated affiliates.
Revenue Fades and Debt Costs Rise
Revenue continues to shrink. The company reported net revenues of $478,000 for the quarter, a sharp drop from $1.4 million in the prior-year period. The cost of servicing its debt is also taking a visible toll. Interest expense rose to $651,000, and the company booked a $278,000 loss on debt extinguishment during the quarter.
The company has been leaning heavily on convertible notes and share issuance to stay afloat. During the quarter, it issued over 4.1 million shares to convert outstanding debt, along with additional shares and warrants tied to new debt deals. The outstanding share count jumped from roughly 9 million to 14 million in just three months, a level of dilution that will concern existing shareholders.
What Comes Next
The filing confirms the company is now in a negative equity position, which can trigger default provisions in lending agreements. The filing also notes that the company was late in filing this report, having checked "No" on the box indicating it has filed all required reports in the preceding 12 months. For investors, the immediate question is whether ProPhase can secure additional financing or generate enough cash from its remaining operations to manage its mounting obligations. The $31,000 cash balance offers virtually no margin for error.